BioCardia Files 8-K: Other Events & Financials
Ticker: BCDA · Form: 8-K · Filed: Aug 13, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, corporate-update
TL;DR
BioCardia dropped an 8-K, check it for company updates and financials.
AI Summary
BioCardia, Inc. filed an 8-K on August 13, 2025, reporting other events and financial statements. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and headquartered in Sunnyvale, California.
Why It Matters
This filing indicates BioCardia is providing updates on its corporate activities and financial status to the SEC, which is important for investors to monitor.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports significant corporate events or financial updates without immediate market-moving news.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- August 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Sunnyvale, California (location) — Address of principal executive offices
FAQ
What specific 'Other Events' are being reported by BioCardia, Inc. in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
When was BioCardia, Inc. previously known as Tiger X Medical, Inc.?
The date of the name change from Tiger X Medical, Inc. to BioCardia, Inc. was June 16, 2011.
What is BioCardia, Inc.'s Standard Industrial Classification (SIC) code?
BioCardia, Inc.'s SIC code is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the SEC file number for BioCardia, Inc.?
The SEC file number for BioCardia, Inc. is 001-38999.
Where is BioCardia, Inc.'s principal executive office located?
BioCardia, Inc.'s principal executive office is located at 320 Soquel Way, Sunnyvale, California 94085.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-08-13 08:00:49
Key Financial Figures
- $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20250812_8k.htm (8-K) — 23KB
- ex_852372.htm (EX-99.1) — 12KB
- 0001437749-25-026356.txt ( ) — 166KB
- bcda-20250813.xsd (EX-101.SCH) — 3KB
- bcda-20250813_def.xml (EX-101.DEF) — 11KB
- bcda-20250813_lab.xml (EX-101.LAB) — 15KB
- bcda-20250813_pre.xml (EX-101.PRE) — 11KB
- bcda20250812_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On August 13, 2025, BioCardia, Inc., a global leader in cellular and cell-directed therapeutics for the treatment of cardiovascular and pulmonary diseases, and CART-Tech, B.V., a provider of vendor independent platform technology for augmented fluoroscopy during cardiac interventions, today issued a joint press release announcing that they have entered into an exclusive development and commercialization agreement for Heart3D Fusion Imaging. The Heart3D system is expected to enhance two-dimensional x-ray images used for cardiac biotherapeutic delivery and biopsy procedures by fusing these images with annotated pre-procedure three-dimensional anatomical heart models created from gold standard MRI and CT images. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated August 13, 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: August 13, 2025